Algorithmic identification of shRNA sequences
Over the years SIRION Biotech has developed its base technology to the point where in 80% of recent projects it managed to identify targeted shRNA sequences with knockdown results of above 90%.
SIRION Biotech offers RNAiONE™ as a guaranteed path to define the most effective small hairpin RNA (shRNA) sequences for target gene identification and validation which can be further translated into SIRION’s viral vector platform.
Combined forces of shRNA-based knockdown delivered by viral vectors
shRNA is an artificial RNA molecule that is used to silence target gene expression via RNA interference (RNAi). shRNA has the following mechanism of action: shRNA binds to the complementary target mRNA in cells, inactivates or degrades the target mRNA leading to gene silencing. In gene therapy this can be relevant to certain types of cancer, where specific mRNAs are elevated.
Expression of shRNA in cells is reached by delivery of shRNA to cells using viral vectors. Different viral vectors can be used to bring shRNA in cells, including adeno-associated viruses (AAV), adenoviruses, and lentiviruses. AAV and adenoviruses do not integrate into genome, so gene expression remains relatively transient. Lentivirus provide a possibility to obtain stable gene expression due to viral genome integration allowing stable knockdown of the target gene.
Successful RNAiONE™ solution for uncovering best possible shRNA sequences
Designing and validation of the best performing shRNAs is essential for effective RNAi knockdown. The key challenge in designing of the effective shRNAs is to isolate the most optimal sequence from millions of possible combinations.
SIRION Biotech’s algorithm-based design of shRNA sequences allows successful identification of 10-15 most active shRNA sequences. The results are fully translatable to SIRION Biotech`s viral vector platforms and allow knockdown efficiency of more than 80 % on mRNA level.
Fields of application
- Gene loss of function studies
- Gene expression silencing
- Target identification & validation for early point drug discovery (e.g. in oncology)
- Cell models generation
- Knockdown guarantee of > 80% on mRNA level
- Results are fully translatable into viral vector platforms
- Full portfolio of RNAiONE compatible viral vector platforms (Lentivirus, Adenovirus, AAV)
- Validated shRNA in less than three weeks
- Documented project statistics
- Customer Satisfaction Guarantee
Contact us to discover more.